Cord Blood News Volume 13.06 | Feb 18 2021

    0
    88







    2021-02-18 | CBN 12.06


    Cord Blood News by STEMCELL Technologies
    Vol. 12.06 – 18 February, 2021
    TOP STORY

    Sequence-Specific 2′-O-Methoxyethyl Antisense Oligonucleotides Activate Human Platelets through Glycoprotein VI, Triggering Formation of Plateletleukocyte Aggregates

    Human cord blood-derived megakaryocytes were treated with antisense oligonucleotides (ASOs) to study effects on proplatelet production. Platelet activation and platelet-leukocyte aggregates were analyzed in ASO-treated blood from healthy human volunteers.
    [Haematologica]

    Abstract
    The StemSpan™ T Cell Generation Kit is designed to promote differentiation of HSPCs into T cells in stroma- and serum-free culture conditions.
    PUBLICATIONSRanked by the impact factor of the journal

    Biological Characteristics of Stem Cells Derived from Burned Skin – a Comparative Study with Umbilical Cord Stem Cells

    Burn-derived MSCs- and umbilical cord-MSCs were compared using immunophenotyping, multi-lineage differentiation, seahorse analysis for glycolytic and mitochondrial function, immune surface markers, and cell secretion profile assays.
    [Stem Cell Research & Therapy]

    Full Article

    Umbilical Mesenchymal Stem Cell-Derived Exosomes Facilitate Spinal Cord Functional Recovery through the miR-199a-3p/145–5p-Mediated NGF/TrkA Signaling Pathway in Rats

    Investigators designed and performed this study to determine whether exosomes attenuate the lesion size of spinal cord injury by ameliorating neuronal injury induced by a secondary inflammatory storm and promoting neurite outgrowth.
    [Stem Cell Research & Therapy]

    Full Article

    Comparison of Anti-Oxidative Effect of Human Adipose- and Amniotic Membrane-Derived Mesenchymal Stem Cell Conditioned Medium on Mouse Preimplantation Embryo Development

    Researchers examined the anti-oxidative potential of human amniotic membrane-derived MSC-conditioned medium treatment during in vitro culture on mouse preimplantation embryo development and antioxidant gene expression in the forkhead box O pathway.
    [Antioxidants]

    Full Article

    Generation of Induced Pluripotent Stem Cell GZHMCi005-A from Amniotic Fluid-Derived Cells with Duplication of Chromosome 8p

    Investigators generated a human induced pluripotent stem cell line from a patient’s amniotic fluid cells with a 18 Mb duplication in 8p23.3p22, which could serve as useful tools for studying duplication of chromosome 8p syndrome.
    [Stem Cell Research]

    Abstract

    Mesenchymal Stem Cell Carriers Enhance Antitumor Efficacy Induced by Oncolytic Reovirus in Acute Myeloid Leukemia

    Human umbilical cord (UC) MSCs were used to deliver reovirus using in vitro and in vivo models. Human UC-MSCs were successfully loaded with reovirus, without impairing biological function
    [International Immunopharmacology]

    Abstract

    Combination Therapy with iRGD-antiCD3 and PD-1 Blockade Enhances Antitumor Potency of Cord Blood-Derived T Cells

    Scientists detected the levels of both PD-1 and PD-L1 as resistance to iRGD-antiCD3 treatment. Using cord blood-derived T cells, they assessed the activation and effects of iRGD-antiCD3 combined with PD-1 as evidenced by activation markers, Th1/Th2-cytokines, and killing capability against tumor cells in vitro.
    [Oncotargets and Therapy]

    Full Article

    Modulatory Activity of Adenosine on the Immune Response in Cord and Adult Blood

    The impact of adenosine on peripheral and cord blood mononuclear cells was analyzed by quantification of ectonucleotidases and adenosine receptor expression.
    [Pediatric Research]

    Abstract
    Use ImmunoCult™ to differentiate mouse CD4+ cells to Tregs.
    REVIEWS

    Human Amniotic Mesenchymal Stem Cells to Promote/Suppress Cancer: Two Sides of the Same Coin

    There are conflicting opinions about the role of human amniotic membrane/fluid MSCs in cancer, as some studies demonstrating the anti-cancer effects of these cells and others suggesting their progressive effects on cancer.
    [Stem Cell Research & Therapy]

    Full Article
    INDUSTRY AND POLICY NEWS

    Mesoblast Phase III Trial Shows That a Single Injection of Rexlemestrocel-L + Hyaluronic Acid Carrier Results in at Least Two Years of Pain Reduction with Opioid Sparing Activity in Patients with Chronic Low Back Pain Due to Degenerative Disc Disease

    Mesoblast Limited announced results from the Phase III randomized controlled trial of its allogeneic mesenchymal precursor cell therapy rexlemestrocel-L in 404 enrolled patients with chronic low back pain due to degenerative disc disease refractory to conventional treatments.
    [Mesoblast, Ltd.]

    Press Release
    FEATURED EVENT

    The American Association for Cancer Research (AACR) Annual Meeting 2021: Week 2

    May 17 – 21, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Position – Hematopoietic Development

    Icahn School of Medicine at Mount Sinai – New York, New York, United States

    Research Associate – Hematopoietic System Development

    St. Jude Children’s Research Hospital – Memphis, Tennessee, United States

    Faculty Position – Department of Hematology

    St. Jude Children’s Research Hospital – Memphis, Tennessee, United States

    Postdoctoral Associate – Epigenetic Mechanisms Governing Hematopoietic Stem Cell Lineage Commitment

    The Jackson Laboratory – Bar Harbor, Maine, United States

    Training Fellowships – Glycosciences

    Blood Research Institute – Milwaukee, Wisconsin, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cord Blood News Twitter